{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:02:07Z","timestamp":1793120527332,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,4,17]],"date-time":"2010-04-17T00:00:00Z","timestamp":1271462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00280-010-1327-8","type":"journal-article","created":{"date-parts":[[2010,4,16]],"date-time":"2010-04-16T12:24:05Z","timestamp":1271420645000},"page":"339-348","source":"Crossref","is-referenced-by-count":50,"title":["Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability"],"prefix":"10.1007","volume":"67","author":[{"given":"Francis","family":"L\u00e9vi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdoulaye","family":"Karabou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Gorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale Fabio","family":"Innominato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Saffroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Giacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Hauteville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Guettier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Bouchahda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,17]]},"reference":[{"key":"1327_CR1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","volume":"10","author":"S Giacchetti","year":"1999","unstructured":"Giacchetti S, Itzhaki M, Gruia G et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663\u2013669","journal-title":"Ann Oncol"},{"key":"1327_CR2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000145964.08365.01","volume":"240","author":"R Adam","year":"2004","unstructured":"Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644\u2013657","journal-title":"Ann Surg"},{"key":"1327_CR3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","volume":"16","author":"G Folprecht","year":"2005","unstructured":"Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311\u20131319","journal-title":"Ann Oncol"},{"key":"1327_CR4","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1200\/JCO.2007.10.8126","volume":"25","author":"R Adam","year":"2007","unstructured":"Adam R, Aloia T, L\u00e9vi F et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593\u20134602","journal-title":"J Clin Oncol"},{"key":"1327_CR5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048","journal-title":"N Engl J Med"},{"key":"1327_CR6","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311\u20132319","journal-title":"J Clin Oncol"},{"issue":"4","key":"1327_CR7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdm516","volume":"19","author":"A Pessino","year":"2008","unstructured":"Pessino A, Artale S, Sciallero S et al (2008) First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol 19(4):711\u2013716","journal-title":"Ann Oncol"},{"key":"1327_CR8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408\u20131417","journal-title":"N Engl J Med"},{"key":"1327_CR9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMe048151","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:391\u2013392","journal-title":"N Engl J Med"},{"key":"1327_CR10","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","volume":"24","author":"HJ Lenz","year":"2006","unstructured":"Lenz HJ, Van Cutsem EV, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914\u20134921","journal-title":"J Clin Oncol"},{"issue":"2","key":"1327_CR11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF02238252","volume":"41","author":"KS Shim","year":"1998","unstructured":"Shim KS, Kim KH, Park BW et al (1998) Increased serum levels of transforming growth factor-alpha in patients with colorectal cancer. Dis Colon Rectum 41(2):219\u2013224","journal-title":"Dis Colon Rectum"},{"key":"1327_CR12","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-04-2000","volume":"11","author":"T Rich","year":"2005","unstructured":"Rich T, Innominato PF, Boerner J et al (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757\u20131764","journal-title":"Clin Cancer Res"},{"key":"1327_CR13","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1126\/science.1067716","volume":"294","author":"A Kramer","year":"2001","unstructured":"Kramer A, Yang FC, Snodgrass P et al (2001) Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 294:2511\u20132515","journal-title":"Science"},{"key":"1327_CR14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.brainres.2005.01.030","volume":"1038","author":"P Snodgrass-Belt","year":"2005","unstructured":"Snodgrass-Belt P, Gilbert JL, Davis FC (2005) Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. Brain Res 1038:171\u2013182","journal-title":"Brain Res"},{"key":"1327_CR15","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.pharmtox.47.120505.105208","volume":"47","author":"F L\u00e9vi","year":"2007","unstructured":"L\u00e9vi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593\u2013628","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1327_CR16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cub.2006.04.026","volume":"16","author":"AB Reddy","year":"2006","unstructured":"Reddy AB, Karp NA, Maywood ES et al (2006) Circadian orchestration of the hepatic proteome. Curr Biol 16:1107\u20131115","journal-title":"Curr Biol"},{"key":"1327_CR17","doi-asserted-by":"crossref","first-page":"10720","DOI":"10.1158\/0008-5472.CAN-06-2086","volume":"66","author":"I Iurisci","year":"2006","unstructured":"Iurisci I, Filipski E, Reinhardt J et al (2006) Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res 66:10720\u201310728","journal-title":"Cancer Res"},{"key":"1327_CR18","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","volume":"86","author":"FA Levi","year":"1994","unstructured":"Levi FA, Zidani R, Vannetzel JM et al (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86:1608\u20131617","journal-title":"J Natl Cancer Inst"},{"key":"1327_CR19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","volume":"350","author":"F Levi","year":"1997","unstructured":"Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350:681\u2013686","journal-title":"Lancet"},{"key":"1327_CR20","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2006.06.1440","volume":"24","author":"S Giacchetti","year":"2006","unstructured":"Giacchetti S, Bjarnason G, Garufi C et al (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24:3562\u20133569","journal-title":"J Clin Oncol"},{"key":"1327_CR21","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.addr.2006.11.001","volume":"59","author":"F L\u00e9vi","year":"2007","unstructured":"L\u00e9vi F, Focan C, Karabou\u00e9 A et al (2007) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59:1015\u20131035","journal-title":"Adv Drug Deliv Rev"},{"key":"1327_CR22","doi-asserted-by":"crossref","unstructured":"Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):38\u201347","DOI":"10.1016\/S1470-2045(09)70330-4"},{"key":"1327_CR23","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Perez-Soler","year":"2005","unstructured":"Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235\u20135246","journal-title":"J Clin Oncol"},{"key":"1327_CR24","doi-asserted-by":"crossref","unstructured":"Tejpar S, Peeters M, Humblet Y et al (2007) Phase I\/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J Clin Oncol 25(Suppl 18S):172s (Abstr 4037)","DOI":"10.1200\/jco.2007.25.18_suppl.4037"},{"key":"1327_CR25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.bjc.6603018","volume":"94","author":"B Vincenzi","year":"2006","unstructured":"Vincenzi B, Santini D, Rabitti C et al (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94:792\u2013797","journal-title":"Br J Cancer"},{"key":"1327_CR26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/annonc\/mdl392","volume":"18","author":"J Souglakos","year":"2007","unstructured":"Souglakos J, Kalykaki A, Vamvakas L et al (2007) Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 18:305\u2013310","journal-title":"Ann Oncol"},{"key":"1327_CR27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdn020","volume":"19","author":"P Pfeiffer","year":"2008","unstructured":"Pfeiffer P, Nielsen D, Bjerregaard J et al (2008) Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 19:1141\u20131145","journal-title":"Ann Oncol"},{"key":"1327_CR28","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1634\/theoncologist.11-10-1072","volume":"11","author":"D Gholam","year":"2006","unstructured":"Gholam D, Giacchetti S, Br\u00e9zault-Bonnet C et al (2006) Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-fluorouracil as ambulatory salvage therapy in patients with Irinotecan- and Oxaliplatin-resistant metastatic colorectal cancer. Oncologist 11:1072\u20131080","journal-title":"Oncologist"},{"key":"1327_CR29","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pharmtox.48.113006.094626","volume":"50","author":"F L\u00e9vi","year":"2010","unstructured":"L\u00e9vi F, Okyar A, Dulong S, Innominato PF, Clairambault J (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:375\u2013419","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1327_CR30","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","volume":"27","author":"R Adam","year":"2009","unstructured":"Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829\u20131835","journal-title":"J Clin Oncol"},{"key":"1327_CR31","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1200\/JCO.2007.13.2183","volume":"25","author":"J Tabernero","year":"2007","unstructured":"Tabernero J, Van Cutsem E, D\u00edaz-Rubio E et al (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225\u20135232","journal-title":"J Clin Oncol"},{"key":"1327_CR32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","volume":"26","author":"A Li\u00e8vre","year":"2008","unstructured":"Li\u00e8vre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374\u2013379","journal-title":"J Clin Oncol"},{"key":"1327_CR33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/sj.bjc.6604439","volume":"99","author":"F Cappuzzo","year":"2008","unstructured":"Cappuzzo F, Varella-Garcia M, Finocchiaro G et al (2008) Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 99:83\u201389","journal-title":"Br J Cancer"},{"key":"1327_CR34","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","volume":"23","author":"KY Chung","year":"2005","unstructured":"Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803\u20131810","journal-title":"J Clin Oncol"},{"key":"1327_CR35","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.cad.0000217425.44584.9f","volume":"17","author":"M Hebbar","year":"2006","unstructured":"Hebbar M, Wacrenier A, Desauw C et al (2006) Lack of usefulness of epidermal growth factor-receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17:855\u2013857","journal-title":"Anticancer Drugs"},{"key":"1327_CR36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","volume":"6","author":"M Moroni","year":"2005","unstructured":"Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279\u2013286","journal-title":"Lancet Oncol"},{"key":"1327_CR37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/annonc\/mdm492","volume":"19","author":"F Cappuzzo","year":"2008","unstructured":"Cappuzzo F, Finocchiaro G, Rossi E et al (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717\u2013723","journal-title":"Ann Oncol"},{"key":"1327_CR38","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2007.11.5956","volume":"25","author":"A Sartore-Bianchi","year":"2007","unstructured":"Sartore-Bianchi A, Moroni M, Veronese S et al (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238\u20133245","journal-title":"J Clin Oncol"},{"key":"1327_CR39","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/annonc\/mdn416","volume":"19","author":"G Milano","year":"2008","unstructured":"Milano G, Etienne-Grimaldi MC, Dahan L et al (2008) Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol 19:2033\u20132038","journal-title":"Ann Oncol"},{"key":"1327_CR40","doi-asserted-by":"crossref","unstructured":"Scartozzi M, Bearzi I, Mandolesi A et al (2009) Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 9:303","DOI":"10.1186\/1471-2407-9-303"},{"key":"1327_CR41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1081\/CBI-100106083","volume":"18","author":"E Haus","year":"2001","unstructured":"Haus E, Dimitriu L, Nicolau GY et al (2001) Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth actor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. Chronobiol Int 18:709\u2013727","journal-title":"Chronobiol Int"},{"key":"1327_CR42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1101\/sqb.2007.72.030","volume":"72","author":"F L\u00e9vi","year":"2007","unstructured":"L\u00e9vi F, Filipski E, Iurisci I et al (2007) Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 72:465\u2013475","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"1327_CR43","first-page":"3038","volume":"6","author":"MC Mormont","year":"2000","unstructured":"Mormont MC, Waterhouse J, Bleuzen P et al (2000) Marked 24-h rest\/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6:3038\u20133045","journal-title":"Clin Cancer Res"},{"key":"1327_CR44","doi-asserted-by":"crossref","unstructured":"Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchatti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Levi F, Bjarnason GA, Chronotherapy Group of the European Organization for Research and Treatment of Cancer (2009) Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 69:4700\u20134707","DOI":"10.1158\/0008-5472.CAN-08-4747"},{"key":"1327_CR45","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1200\/JCO.2007.11.3274","volume":"25","author":"I Iurisci","year":"2007","unstructured":"Iurisci I, Rich T, L\u00e9vi F et al (2007) Relief of symptoms after Gefitinib is associated with improvement of rest\/activity rhythm in advanced lung cancer. J Clin Oncol 25:e17\u2013e19","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1327-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1327-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1327-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:23:30Z","timestamp":1591215810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1327-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,17]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1327-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,17]]}}}